Fagron NV
XBRU:FAGR

Watchlist Manager
Fagron NV Logo
Fagron NV
XBRU:FAGR
Watchlist
Price: 16.98 EUR -0.93% Market Closed
Market Cap: 1.2B EUR
Have any thoughts about
Fagron NV?
Write Note

Fagron NV
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fagron NV
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Fagron NV
XBRU:FAGR
Cash from Financing Activities
-€74.3m
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Fagron NV
Glance View

Market Cap
1.2B EUR
Industry
Health Care

Fagron NV is a Belgian multinational company that has woven specialized pharmaceutical compounding into the fabric of modern healthcare. Founded in 1990, the company's mission has always been to advance personalized medicine by focusing on the compounding sector, which involves tailoring and mixing pharmaceutical ingredients to produce unique medications tailored to the specific needs of patients. By transforming individual healthcare demands into bespoke pharmaceutical solutions, Fagron serves the global medical community by manufacturing and distributing both active and inactive pharmaceutical ingredients, as well as offering various base products. This strategic positioning not only supports healthcare professionals and pharmacies in delivering specialized patient care but also fortifies the company's commitment to improving global health outcomes. The key to Fagron's business model lies in its adept integration of innovation alongside therapeutic and technological solutions, ensuring they maintain a strong presence within the compounding market. The company particularly thrives on its ability to address niches in the pharmaceutical industry, ones often overlooked by large pharma entities due to scale inefficiencies. Through its three principal segments—Pharmaceutical Compounding, Raw Materials, and Innovative Concepts—Fagron generates revenue by supplying pharmacies and medical institutions worldwide, from small community pharmacies to large hospital networks. Its broad portfolio of over 30,000 products caters to a spectrum of needs, fostering both patient-specific and bulk pharmaceutical solutions. By combining quality, safety, and regulatory compliance with a keen market understanding, Fagron NV continues to sustain its role as a crucial player in the personalized medicine arena.

FAGR Intrinsic Value
26.65 EUR
Undervaluation 36%
Intrinsic Value
Price

See Also

What is Fagron NV's Cash from Financing Activities?
Cash from Financing Activities
-74.3m EUR

Based on the financial report for Dec 31, 2023, Fagron NV's Cash from Financing Activities amounts to -74.3m EUR.

What is Fagron NV's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-12%

The average annual Cash from Financing Activities growth rates for Fagron NV have been -12% over the past three years .

Back to Top